Explore our corporate updates and press releases below. For the latest news, follow us on LinkedIn.

To learn more about our company, visit our Corporate Overview page. To see our progress toward new answers and disease-centric therapies, visit our Pipeline page or review recent articles and studies on our Publications page.

Date Title
03/18/2022 Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference Press Release
03/01/2022 Ichnos Sciences Welcomes Eugene Zhukovsky, Ph.D., as New Chief Scientific Officer Press Release
02/28/2022 Ichnos Sciences Announces Formation of Scientific Advisory Board to Inform Research and Development Strategy in Immuno-Oncology Press Release
12/14/2021 Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody Press Release
12/11/2021 Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting Press Release
11/09/2021 Ichnos Sciences Appoints Sonia Quaratino, M.D., PH.D., to its Board Of Directors Press Release
11/08/2021 Ichnos Sciences Welcomes Eric Feldman, M.D., as New Chief Medical Officer Press Release
08/06/2021 Ichnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma Press Release
06/04/2021 Ichnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting Press Release
05/03/2021 Ichnos Sciences Presents Positive Data from Ongoing Phase 2b Study of Telazorlimab in Atopic Dermatitis at the 2021 SID Virtual Meeting Press Release

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.